233280-30-3

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Chlorothiophene-2-Methanol is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 4-Chlorothiophene-2-Methanol serves as a vital component in the creation of various agrochemicals, contributing to the development of effective solutions for agricultural needs.
Used in Organic Compounds Synthesis:
4-Chlorothiophene-2-Methanol is utilized as a versatile building block in the synthesis of other organic compounds, showcasing its reactivity and importance in organic chemistry.
Used in Fine Chemicals Production:
4-Chlorothiophene-2-Methanol is employed as an intermediate in the production of various fine chemicals, highlighting its role in creating specialty chemicals for specific applications.
Used in Material Development:
4-Chlorothiophene-2-Methanol is also utilized in the development of new materials, indicating its potential in contributing to advancements in material sciences.
Used in Organic Chemistry Research:
As a reagent in organic chemistry research, 4-Chlorothiophene-2-Methanol aids in conducting experiments and exploring new chemical reactions, further expanding the understanding of organic chemistry.

Upstream product

• 17249-80-8 3-chlorothiophene 
• 124-38-9 carbon dioxide 
• 59614-95-8 4-Chloro-2-thiophenecarboxylic Acid 

Relevant academic research and scientific papers

Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold

Glucose regulated protein 94 (Grp94) is the endoplasmic reticulum resident of the heat shock protein 90 kDa (Hsp90) family of molecular chaperones. Grp94 associates with many proteins involved in cell adhesion and signaling, including integrins, Toll-like receptors, immunoglobulins, and mutant myocilin. Grp94 has been implicated as a target for several therapeutic areas including glaucoma, cancer metastasis, and multiple myeloma. While 85% identical to other Hsp90 isoforms, the N-terminal ATP-binding site of Grp94 possesses a unique hydrophobic pocket that was used to design isoform-selective inhibitors. Incorporation of a cis-amide bioisostere into the radamide scaffold led to development of the original Grp94-selective inhibitor, BnIm. Structure-activity relationship studies have now been performed on the aryl side chain of BnIm, which resulted in improved analogues that exhibit better potency and selectivity for Grp94. These analogues also manifest superior antimigratory activity in a metastasis model as well as enhanced mutant myocilin degradation in a glaucoma model compared to BnIm.

NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS

The invention relates to novel heterocyclic acrylamide compounds (I), to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.